EPHA3 and glioblastoma: Such heterogeneity in expression, as further quantified in primary GBM tumors (figure 1D), highlights the need for personalized approaches in CAR T cell therapy, potentially guided by EphA3 expression levels to maximize therapeutic outcomes.